ELIC — Elicera Therapeutics AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK270.83m
- SEK245.98m
- SEK10.86m
Annual cashflow statement for Elicera Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.1 | -19.4 | -17.1 | -16.9 | -17.9 |
| Amortisation | |||||
| Changes in Working Capital | -1.19 | 10.8 | 2.16 | -6.59 | -3.61 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -14.3 | -8.57 | -14.9 | -23.5 | -21.6 |
| Capital Expenditures | — | — | -0.001 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.001 | 0 | 0.484 | 0 | 0.001 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | -0.001 | 0 | 0.483 | 0 | 0.001 |
| Financing Cash Flow Items | — | — | — | — | -2.03 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 55.1 | 0 | 0 | 20.5 | 20 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 40.8 | -8.57 | -14.4 | -2.98 | -1.55 |